| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 7.873 | 15.820 | 17.076 | 34.749 | 28.668 | 27.276 | 36.819 | 41.760 | 40.470 |
| Total Income - EUR | - | 7.873 | 15.820 | 17.076 | 34.749 | 28.668 | 27.276 | 36.870 | 42.093 | 40.470 |
| Total Expenses - EUR | - | 11.610 | 29.361 | 28.282 | 27.191 | 25.342 | 25.353 | 34.786 | 38.450 | 35.612 |
| Gross Profit/Loss - EUR | - | -3.737 | -13.541 | -11.205 | 7.559 | 3.326 | 1.922 | 2.084 | 3.643 | 4.858 |
| Net Profit/Loss - EUR | - | -3.895 | -13.883 | -11.376 | 6.516 | 2.495 | 1.104 | 978 | 3.086 | 4.227 |
| Employees | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Otomed Research Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | 941 | 1.427 | 1.578 | 8.285 | 11.289 | 16.044 | 22.196 | 20.867 | 24.917 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 0 | 493 | 322 | 0 | 5.729 | 10.647 | 15.740 | 17.122 | 18.093 |
| Cash | - | 941 | 934 | 1.256 | 8.285 | 5.560 | 5.396 | 6.456 | 3.745 | 6.824 |
| Shareholders Funds | - | -3.850 | -17.668 | -11.217 | -4.483 | -1.901 | -755 | 221 | 3.306 | 19.619 |
| Social Capital | - | 45 | 44 | 9.670 | 9.483 | 9.305 | 9.099 | 9.127 | 9.099 | 9.250 |
| Debts | - | 5.797 | 19.293 | 12.846 | 12.824 | 13.339 | 16.961 | 22.117 | 17.712 | 6.500 |
| Income in Advance | - | 804 | 814 | 950 | 957 | 957 | 951 | 953 | 954 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7210 - 7210" | |||||||||
| CAEN Financial Year |
7219
|
|||||||||
Comments - Otomed Research Srl